Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

Clinical trial NCT06552429 · RECRUITING

Trial details

NCT number: NCT06552429
Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Essential Thrombocythemia

Start date: 2024-08-29
Primary completion: 2025-10-26
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.